Zelira Therapeutics Ltd
ZLD
Company Profile
Business description
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer.
Contact
101 St George’s Terrace
Level 3
PerthWA6000
AUST: +61 865580886
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
8
Stocks News & Analysis
stocks
Anglo American strikes deal to create a new copper giant
We are surprised that Teck agreed to the merger on these terms, and wouldn’t be surprised if there is a twist in the tale.
stocks
The ‘other’ AI chip behemoth that might just be getting started
The magnitude of growth at Broadcom continues to astound us.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,071.40 | 9.10 | -0.10% |
| CAC 40 | 7,823.52 | 62.20 | 0.80% |
| DAX 40 | 23,703.65 | 70.70 | 0.30% |
| Dow JONES (US) | 46,078.10 | 587.18 | 1.29% |
| FTSE 100 | 9,297.58 | 72.19 | 0.78% |
| HKSE | 26,086.32 | 113.94 | -0.43% |
| NASDAQ | 22,045.66 | 159.60 | 0.73% |
| Nikkei 225 | 44,372.50 | 534.83 | 1.22% |
| NZX 50 Index | 13,229.15 | 47.09 | -0.35% |
| S&P 500 | 6,585.88 | 53.84 | 0.82% |
| S&P/ASX 200 | 8,805.00 | 8.80 | -0.10% |
| SSE Composite Index | 3,875.31 | 63.09 | 1.65% |